

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司

Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China)

(Stock Code: 8189)

PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION

On 17 February 2023, the China Securities Regulatory Commission (the “CSRC”) promulgated the Trial Administrative Measures for the Overseas Issuance and Listing of Securities by Domestic Enterprises (CSRC Announcement No. 43 of 2023), article 6 of which expressly provides that “a domestic enterprise conducting overseas issuance and listing shall, in accordance with the Company Law of the People's Republic of China, the Accounting Law of the People's Republic of China and other laws, administrative regulations and relevant state provisions, formulate its articles of association, improve its internal control systems, and regulate its corporate governance and financial and accounting practices.” The Company Law of the People's Republic of China was revised and adopted on 29 December 2023 and has come into effect since 1 July 2024.

The Board hereby proposes that, in accordance with the newly promulgated Trial Administrative Measures for the Overseas Issuance and Listing of Securities by Domestic Enterprises and Articles 152 and 153 of the Company Law of the People's Republic of China, the following clauses be added to the Articles of Association of the Company: “The Articles of Association authorise the Board to resolve, within three years, to issue shares not exceeding 50% of the issued shares. However, where capital contribution is made with non-monetary property, a resolution of the shareholders' meeting shall be required. Where the issue of shares resolved by the Board pursuant to the preceding paragraph results in any change to the registered capital or the number of issued shares of the Company, no further vote at a shareholders' meeting shall be required for the amendment of such particulars as recorded in the Articles of Association. Where the Articles of Association authorise the Board to resolve to issue new shares, the resolution of the Board shall be passed by more than two-thirds of all directors. In exercising this authorisation, the Board shall comply with the securities regulatory rules of the place where the shares of the Company are listed.”

The above proposed amendment to the Articles of Association is subject to the approval of the shareholders by way of a special resolution at an extraordinary general meeting of the Company and the fulfilment of the filing requirements with the Administration for Industry and Commerce before it can take effect. A notice convening the extraordinary general meeting containing details of the relevant special resolution will be dispatched to the shareholders as soon as practicable, together with a circular including details of the proposed amendment to the Articles of Association.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the meanings set out below:

“Administration for Industry and Commerce”	the Tianjin Administration for Industry and Commerce of the PRC
“Articles of Association”	the articles of association of the Company, as amended, revised or otherwise supplemented from time to time
“Board”	the board of directors of the Company
“the Company”	Tianjin TEDA Biomedical Engineering Company Limited, a joint stock company incorporated in the PRC, the H shares of which are listed and traded on GEM (Stock Code: 8189)
“EGM”	the extraordinary general meeting of the Company to be convened
“GEM”	GEM of the Stock Exchange
“GEM Listing Rules”	the Rules Governing the Listing of Securities on GEM
“Group”	the Company and its subsidiaries
“Shareholders”	the shareholders of the Company

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Chairman
Sun Li

Tianjin, the PRC
7 September 2026

As at the date of this announcement, the executive directors of the Company are Ms. Sun Li and Mr. Yang Zeng; the non-executive directors of the Company are Mr. He Xin, Dr. Li Ximing, Mr. Wang Lei and Mr. Xia Alan Zhe; and the independent non-executive directors of the Company are Ms. Gao Chun, Mr. Tu Xiangzhen and Mr. Chen Jiang.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com, on the “Latest Company Announcements” page, for at least seven days from the date of its posting and will also be published and made available on the website of the Company at www.bioteda.com.